126 related articles for article (PubMed ID: 30972956)
1. Comparison of expression optimization of new derivative of staphylokinase (SAK-2RGD-TTI) with the rSAK.
Faraji H; Ramezani M; Mashkani B; Sadeghnia HR; Benhangi HM; Hosseini Teshnizi S; Soltani F
Biotechnol Prog; 2019 Jul; 35(4):e2819. PubMed ID: 30972956
[TBL] [Abstract][Full Text] [Related]
2. Designing a multifunctional staphylokinase variant (SAK-2RGD-TTI) with appropriate thrombolytic activity in vitro.
Faraji H; Soltani F; Ramezani M; Sadeghnia HR; Nedaeinia R; Moghimi Benhangi H; Mashkani B
Biotechnol Lett; 2020 Jan; 42(1):103-114. PubMed ID: 31686286
[TBL] [Abstract][Full Text] [Related]
3. High-level expression of a biologically active staphylokinase in Pichia pastoris.
Faraji H; Ramezani M; Sadeghnia HR; Abnous K; Soltani F; Mashkani B
Prep Biochem Biotechnol; 2017 Apr; 47(4):379-387. PubMed ID: 27813714
[TBL] [Abstract][Full Text] [Related]
4. Characterization of a novel bifunctional mutant of staphylokinase with platelet-targeted thrombolysis and antiplatelet aggregation activities.
Chen H; Mo W; Su H; Zhang Y; Song H
BMC Mol Biol; 2007 Oct; 8():88. PubMed ID: 17919340
[TBL] [Abstract][Full Text] [Related]
5. [Expression, purification and characterization of a novel staphylokinase with anti-platelet aggregation activity].
Jingfang D; Jintian H; Ruiguang X; Xi C; Baohua Z
Wei Sheng Wu Xue Bao; 2008 Sep; 48(9):1186-91. PubMed ID: 19062642
[TBL] [Abstract][Full Text] [Related]
6. Fusion proteins with anticoagulant and fibrinolytic properties: functional studies and structural considerations.
Icke C; Schlott B; Ohlenschläger O; Hartmann M; Gührs KH; Glusa E
Mol Pharmacol; 2002 Aug; 62(2):203-9. PubMed ID: 12130670
[TBL] [Abstract][Full Text] [Related]
7. In vitro characterization of a multifunctional staphylokinase variant with reduced reocclusion, produced from salt inducible E. coli GJ1158.
Pulicherla KK; Kumar A; Gadupudi GS; Kotra SR; Rao KR
Biomed Res Int; 2013; 2013():297305. PubMed ID: 23998121
[TBL] [Abstract][Full Text] [Related]
8. A new recombinant thrombolytic and antithrombotic agent with higher fibrin affinity--a staphylokinase variant. I. In vitro study.
Szemraj J; Walkowiak B; Kawecka I; Janiszewska G; Buczko W; Bartkowiak J; Chabielska E
J Thromb Haemost; 2005 Oct; 3(10):2156-65. PubMed ID: 16150047
[TBL] [Abstract][Full Text] [Related]
9. Functional properties of a novel mutant of staphylokinase with platelet-targeted fibrinolysis and antiplatelet aggregation activities.
Chen H; Mo W; Zhang Y; Su H; Ma J; Yao R; Zhang S; Ge J; Song H
Eur J Pharmacol; 2007 Jul; 566(1-3):137-44. PubMed ID: 17451675
[TBL] [Abstract][Full Text] [Related]
10. High-level expression of non-glycosylated and active staphylokinase from Pichia pastoris.
Apte-Deshpnade A; Mandal G; Soorapaneni S; Prasad B; Kumar J; Padmanabhan S
Biotechnol Lett; 2009 Jun; 31(6):811-7. PubMed ID: 19214390
[TBL] [Abstract][Full Text] [Related]
11. Novel recombinant thrombolytic and antithrombotic staphylokinase variants with an RGD motif at their N-termini.
He J; Di J; Xu R; Zhao B
Biotechnol Appl Biochem; 2008 May; 50(Pt 1):17-23. PubMed ID: 18039183
[TBL] [Abstract][Full Text] [Related]
12. Cloning and expression of a new recombinant thrombolytic and anthithrombotic agent - a staphylokinase variant.
Kowalski M; Brown G; Bieniasz M; Oszajca K; Chabielska E; Pietras T; Szemraj Z; Makandjou-Ola E; Bartkowiak J; Szemraj J
Acta Biochim Pol; 2009; 56(1):41-53. PubMed ID: 19018330
[TBL] [Abstract][Full Text] [Related]
13. High yielding recombinant Staphylokinase in bacterial expression system--cloning, expression, purification and activity studies.
Mandi N; Soorapaneni S; Rewanwar S; Kotwal P; Prasad B; Mandal G; Padmanabhan S
Protein Expr Purif; 2009 Mar; 64(1):69-75. PubMed ID: 19000928
[TBL] [Abstract][Full Text] [Related]
14. Refolding of a staphylokinase variant y1-Sak by reverse dilution.
He J; Wang G; Xu R; Feng J; Wang J; Su H; Song H
Appl Biochem Biotechnol; 2008 Oct; 151(1):29-41. PubMed ID: 18785020
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of a multifunctional staphylokinase variant with thrombin inhibition and antiplatelet aggregation activities produced from salt-inducible E. coli GJ1158.
Kumar A; Pulicherla KK; Mayuren C; Kotra S; Rao KR
Can J Physiol Pharmacol; 2013 Oct; 91(10):839-47. PubMed ID: 24144055
[TBL] [Abstract][Full Text] [Related]
16. A new recombinant thrombolytic and antithrombotic agent with higher fibrin affinity - a staphylokinase variant. An in-vivo study.
Szemraj J; Stankiewicz A; Rozmyslowicz-Szermińska W; Mogielnicki A; Gromotowicz A; Buczko W; Oszajca K; Bartkowiak J; Chabielska E
Thromb Haemost; 2007 Jun; 97(6):1037-45. PubMed ID: 17549308
[TBL] [Abstract][Full Text] [Related]
17. New derivative of staphylokinase SAK-RGD-K2-Hirul exerts thrombolytic effects in the arterial thrombosis model in rats.
Szemraj J; Zakrzeska A; Brown G; Stankiewicz A; Gromotowicz A; Grędziński T; Chabielska E
Pharmacol Rep; 2011; 63(5):1169-79. PubMed ID: 22180359
[TBL] [Abstract][Full Text] [Related]
18. Expression and intein-mediated purification of novel staphylokinase SakSTAR with reduced immunogenicity and antiplatelet and antithrombin activation.
Kochanowski R; Kotlowski R; Szweda P
Appl Biochem Biotechnol; 2007; 141(2-3):321-33. PubMed ID: 18025559
[TBL] [Abstract][Full Text] [Related]
19. Construction and characterization of a novel staphylokinase variant with thrombin-inhibitory activity.
Wang M; Wang Y; Wang J; Zou M; Liu S; Xu T; Cai X; Wu C; Wang J; Xu D
Biotechnol Lett; 2009 Dec; 31(12):1923-7. PubMed ID: 19685208
[TBL] [Abstract][Full Text] [Related]
20. Inhibitory effect of staphylokinase on platelet aggregation.
Suehiro A; Oura Y; Ueda M; Kakishita E
Thromb Haemost; 1993 Nov; 70(5):834-7. PubMed ID: 7510426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
